Daily Issue | oct 21, 2016
Stocks rattled around the unchanged line over the past week as investors balanced a mostly positive set of quarterly earnings reports with a mostly negative set of economic data updates.
Mix in more comments from Federal Reserve officials suggesting that the next round of multiple interest rate hikes will start in December, come hell or high water, and investors just did not feel very motivated to buy in bulk this week.
In today’s Trader’s Advantage, we’ll focus on our Pentaphor trades as well as the other open positions in our portfolio.
Daily Issue | oct 20, 2016
Stocks started in the red this morning, tried to get up off the mat a few times, but kept getting trampled.
This is very odd behavior for the third week of October, particularly in an election year, as investors should be celebrating some fairly decent earnings reports and looking past the trough of weak earnings to a better, brighter environment ahead. Instead, investors are selling at every opportunity.
In today's Trader's Advantage, we’ll look at our Pentaphor trades, review some open positions, and check back in on the Watch List.
Daily Issue | oct 19, 2016
Stocks were higher in quiet late afternoon trading amid a busy round of earnings and some mostly disappointing data on home building.
Energy and financials topped the gainers list, while consumer staples and utilities lagged. Crude oil and gold were both higher.
In today's Trader's Advantage, we’ll cover all our Pentaphor trades, review the open positions, and even take a peek at a few stocks on my Watch List.
Daily Issue | oct 18, 2016
Stocks were higher in quiet, stable late afternoon trading after opening with a gap up that resulted from some positive Q3 earnings reports.
New inflation data has also motivated investors, as it potentially helps keep the Federal Reserve on the sidelines.
In today's Trader's Advantage, we’ll cover the latest set of Pentaphor trades, review two new plays and one to keep an eye on. We will also cancel an open order and finish up with a look at the rest of our current recommendations.